Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520linagliptin

# Linagliptin ## Overview Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is characterized by predominantly non-renal excretion. ## Primary Indications Type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. ## Adult Dosing 5 mg orally once daily. May be taken with or without food. ## Pediatric Dosing Safety and effectiveness in pediatric patients (younger than 18 years) have not been established. ## Dose Adjustments * **Renal Impairment:** No dosage adjustment required. * **Hepatic Impairment:** No dosage adjustment required. * **Elderly:** No dosage adjustment required. ## Contraindications * Hypersensitivity to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions). * History of pancreatitis (use with caution). ## Adverse Effects * **Common:** Nasopharyngitis. * **Serious:** Acute pancreatitis (seek immediate care if severe abdominal pain occurs), bullous pemphigoid (report blistering/erosion), joint pain (arthralgia, can be severe/disabling), and hypersensitivity reactions. * **Hypoglycemia:** Low risk when used as monotherapy; risk increases when combined with insulin or insulin secretagogues (e.g., sulfonylureas). ## Key Drug Interactions * **Strong CYP3A4/P-gp Inducers (e.g., Rifampin):** May decrease linagliptin plasma concentrations. If co-administration is necessary, consider increasing monitoring or using an alternative agent. * **Insulin/Sulfonylureas:** May require dosage reduction of the partner secretagogue to prevent hypoglycemia. ## Monitoring * **Glycemic Control:** HbA1c (typically every 3–6 months) and fingerstick blood glucose monitoring. * **Pancreatitis:** Monitor for symptoms (persistent, severe abdominal pain often radiating to the back). * **Skin:** Monitor for blistering/ulceration. ## Clinical Pearls * **Elimination:** Unlike other DPP-4 inhibitors (e.g., sitagliptin, saxagliptin), linagliptin is primarily excreted via the biliary/fecal route, making it the preferred agent in patients with chronic kidney disease. * **No Weight Change:** Linagliptin is considered weight-neutral. * **Dosing Integrity:** Do not split or crush tablets. *** *Disclaimer: This information is for educational purposes only. Clinical practices vary by institution and patient-specific factors. Always verify the latest prescribing information and local clinical protocols before administering or prescribing any medication.*